Can a patient with severe mental illness who has gained more than 3% of baseline weight on olanzapine and is taking metformin still experience weight loss after discontinuing olanzapine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Weight Loss After Discontinuing Olanzapine

Yes, patients can experience weight loss after discontinuing olanzapine, particularly when the medication causing weight gain is removed and replaced with weight-neutral alternatives or when adjunctive weight management strategies like metformin are continued. The American Diabetes Association explicitly recommends minimizing medications associated with weight gain whenever possible, specifically naming olanzapine as a problematic agent 1.

Mechanism and Expected Outcomes

Discontinuing olanzapine removes the primary driver of weight gain, allowing for potential weight reversal, especially when combined with ongoing metformin therapy.

  • Olanzapine is well-documented to cause substantial weight gain through appetite stimulation and metabolic changes, with long-term studies showing mean weight gain of 5.6 kg and 64% of patients gaining at least 7% of baseline weight 2
  • The weight-promoting effects of olanzapine are medication-specific and reversible upon discontinuation 1
  • Metformin achieves approximately 3% weight loss when used for antipsychotic-induced weight gain, with 25-50% of participants achieving at least 5% weight loss 3

Clinical Strategy for Weight Loss Post-Discontinuation

Continue metformin therapy after stopping olanzapine to maximize weight loss potential, as the combined effect of removing the weight-promoting agent and maintaining the weight-reducing agent creates optimal conditions for weight reduction.

Immediate Actions:

  • Continue metformin at current dose (target 1000 mg twice daily if tolerated, as doses >1500 mg daily show greatest weight loss) 3
  • Implement intensive lifestyle modifications including dietary counseling and physical activity, which are essential adjuncts 1, 3
  • Monitor weight weekly for the first month, then monthly 3

Expected Timeline:

  • Initial weight loss typically occurs within 3 months of removing the offending antipsychotic 1
  • Case reports demonstrate dramatic weight loss (14-15 kg) can occur within 12 months after switching away from olanzapine 4
  • One case report showed 37 lb weight loss over 4 months when aripiprazole was added to olanzapine (though this involved medication addition rather than discontinuation) 5

Monitoring Requirements

Assess response at 3-6 months to determine if additional interventions are needed.

  • Baseline and ongoing monitoring should include BMI, waist circumference, blood pressure, HbA1c, glucose, and lipids 3
  • Annual liver function tests, HbA1c, renal function, and vitamin B12 levels during continued metformin therapy 3
  • If <5% weight loss after 3 months, consider escalating metformin dose or adding alternative weight-loss medications 1, 3

Alternative Interventions if Weight Loss Insufficient

If weight loss remains inadequate after 3-6 months despite discontinuing olanzapine and continuing metformin, consider FDA-approved weight-loss medications.

  • GLP-1 receptor agonists (liraglutide 3 mg daily achieves 6% weight loss) may be considered, though cost and insurance coverage are barriers 1, 3
  • Orlistat (blocks 30% of fat absorption) could be considered, particularly if constipation is present 1, 3
  • Phentermine/topiramate ER or bupropion/naltrexone SR are additional FDA-approved options for patients with BMI ≥27 kg/m² with comorbidities 1

Critical Caveats

The degree of weight loss depends heavily on whether the patient was switched to another antipsychotic or completely discontinued antipsychotic therapy.

  • If switched to another antipsychotic, choose weight-neutral agents like lurasidone or ziprasidone to avoid continued weight gain 3
  • In chronic schizophrenic patients previously exposed to multiple antipsychotics, appetite changes may be less pronounced than in drug-naive patients 6
  • Weight loss is most dramatic when olanzapine is completely removed rather than dose-reduced 4, 5

Related Questions

What medication can be prescribed for a patient with significant weight loss and decreased appetite, taking risperidone, Prozac (fluoxetine), and Cogentin (benztropine)?
Can aripiprazole cause decreased appetite?
Can the regular oral olanzapine tablet be switched to the rapid‑disintegrating (ODT) formulation at the same dose?
Can immediate‑release metformin be dosed 1000 mg in the morning and 500 mg in the evening for a patient with olanzapine‑induced weight gain?
What alternative antipsychotic medication to Abilify (Aripiprazole) can be used for a patient concerned about weight gain?
How should I evaluate and manage headache in a patient with beta‑thalassemia receiving chronic transfusions and iron‑chelation therapy?
For a postpartum woman with uncomplicated mastitis and no known drug allergies, which oral antibiotic is preferred: cloxacillin, clindamycin, or sultamicillin?
What are the steps of a robotic McKeown esophagectomy in an adult patient with resectable distal or mid‑esophageal cancer who is medically fit for minimally invasive surgery?
In a patient with acute influenza‑like illness onset within 48 hours, can I initiate oseltamivir (Tamiflu) based solely on symptoms, and what is the appropriate dosing for adults, children, and those with renal impairment?
In a 57-year-old patient with type 2 diabetes on metformin who develops bacterial pneumonia, is the lactic acidosis more likely caused by the infection or by metformin?
What is the lowest effective dose of stimulant medications (e.g., methylphenidate, amphetamine, lisdexamfetamine) for an adult with attention‑deficit/hyperactivity disorder who has no contraindications such as uncontrolled hypertension, significant cardiac disease, history of stimulant misuse, or severe anxiety?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.